Q3 FY2026 · ended Sep 30, 2026 · Revenue $5.62M, +18.0% YoY · Filed Nov 5, 2026
Nephros, Inc. (NEPH) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In Q3 of fiscal 2026, the quarter ended Sep 30, 2026, it reported revenue of $5.6 million and net income of $512,000. As of Sep 30, 2026 it held $4.5 million in cash and investments and $774,000 in total debt.
Revenue
$5.62M
+18.0% vs year-ago quarter
Net income
$512,000
+51.9% vs year-ago quarter
Operating cash flow
$-150,000
-251.5% vs year-ago quarter
Free cash flow
$1.30M
EPS
$0.05
+66.7% vs year-ago quarter
Dividend per share
None
Shares outstanding
10.87M
+2.3% vs year-ago quarter
Net cash
$3.77M
Q3 FY2026
Operating margin
8.5%
TTM
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- NEPH (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- South Orange, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1196298
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q3 FY2026 Sep 30, 2026 |
Q2 FY2026 Jun 30, 2026 |
Q1 FY2026 Mar 31, 2026 |
Q4 FY2025 Dec 31, 2025 |
Q3 FY2025 Sep 30, 2025 |
|---|---|---|---|---|---|
| Revenue | $5.6M | $6.0M | $5.2M | $4.7M | $4.8M |
| Operating income | $501,000 | $1.2M | $97,000 | $18,000 | $314,000 |
| Net income | $512,000 | $1.2M | $140,000 | $62,000 | $337,000 |
| Diluted EPS | $0.05 | $0.11 | $0.01 | $0.01 | $0.03 |
| Operating cash flow | -$150,000 | $681,000 | -$1.7M | $185,000 | $99,000 |
| Total assets | $15.3M | $15.8M | $13.8M | $13.6M | $13.2M |
| Total liabilities | $2.8M | $3.8M | $3.1M | $3.4M | $3.2M |
| Stockholders' equity | $12.5M | $12.0M | $10.7M | $10.2M | $10.0M |
| Cash and investments | $4.5M | $4.7M | $4.0M | $5.4M | $5.2M |
| Total debt | $774,000 | $872,000 | $968,000 | $1.1M | $1.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Aug 6, 2026 |
| 10-Q | Quarterly report | Nov 5, 2026 | Sep 30, 2026 |
| 8-K |
Current report
Other events
|
Oct 13, 2026 | Oct 13, 2026 |
| 10-Q | Quarterly report | Aug 10, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Jun 15, 2026 | Jun 12, 2026 |
All 1005 Nephros, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.